Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma

Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis

(2013) Beatrice Nardone et al.   Clinical Lymphoma Myeloma & Leukemia

Desensitization to Lenalidomide in a Patient With Relapsed Multiple Myeloma

(2012) Jack T. Seki et al.   Clinical Lymphoma Myeloma & Leukemia

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602

(2011) Giuseppa Penna et al.   ACTA ONCOLOGICA

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY